CPT may provide clinicians with a therapeutic alternative due to

CPT may provide clinicians with a therapeutic alternative due to enhanced activity when faced with MRSA isolates with elevated glyco- or lipopeptide MICs, such as hVISA, VISA, or DNS strains. However, additional research is warranted to determine the clinical utility of this phenomenon. Acknowledgments No funding or sponsorship was received for this study or publication of this article. MJR has received grant support,

consulted for, or provided lectures for Cubist, Durata, Forest, Novartis and Sunovion, Theravance and funding in part by NIH NIAID R21A1092055-01. KEB, CEI, and NB have no potential conflicts of interest to declare. We thank George Sakoulas for providing strains (A8090, A8091, D592, and D712) for AZD6738 this research. Michael J. Rybak is the guarantor for this article and takes responsibility for the integrity of the work as a whole. Compliance with ethics This article does not contain any studies with MCC-950 human or animal subjects performed by any of the authors. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. Electronic

supplementary material Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 202 kb) References 1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety

Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14 (Epub 2012/12/12).PubMedCrossRef 2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29(11):996–1011 (Epub 2008/10/25).PubMedCrossRef 3. van Hal SJ, Paterson DL. Systematic review and meta-analysis Tyrosine-protein kinase BLK of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(1):405–10 (Epub 2010/11/17).PubMedCentralPubMedCrossRef 4. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398–402 (Epub 2004/06/09).PubMedCentralPubMedCrossRef 5. Neoh HM, Hori S, Komatsu M, Oguri T, Takeuchi F, Cui L, et al.

Comments are closed.